QualityStocks News – Power of the Dream Ventures Subsidiary Partners with German Cancer Research Center to Tackle HPV …

Posted: Published on October 13th, 2012

This post was added by Dr Simmons

Collaboration will initiate preclinical research aimed at developing a treatment for Human Papilloma Virus after infection has occurred

Scottsdale, Arizona (PRWEB) October 13, 2012

In the companys news yesterday,

Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures, has inked an agreement with DKFZ (German Cancer Research Center, Heidelberg, Germany) to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical and other cancers. The companies are addressing a gap in the market between vaccines such as Cervarix and Gardasil, which have no therapeutic effect on HPV-related diseases, and the need for a product to treat diseases or conditions caused by HPV.

There is a huge unmet medical need for such cancer vaccine, because vaccines we have developed earlier do not provide protection against cancer when used for treatment of existing conditions caused by HPV. Our goal is to provide protection against cancer for patients after the onset of sexual activity, after they might be exposed to HPV, Dr. Julianna Lisziewicz, CEO of Genetic Immunity stated in the press release.

The Division of Genome Modifications and Carcinogenesis will commence a preclinical research program to evaluate the therapeutic efficacy of the DKFZs HPV-specific plasmid DNA using Genetic Immunitys nanomedicine formulation and Langerhans cell-targeting administration technologies.

The newly formed collaboration will use Genetic Immunitys clinically proven technology, as demonstrated in clinical trials of DermaVir as an immunotherapy for the cure of HIV, in its research. The collaboration will test whether HPV-specific memory T cells induced by Genetic Immunitys nanomedicine products could protect against cancer after infection has already occurred.

We found that Genetic Immunity technology is unique to target the vaccine DNA into the nucleus of the Langerhans cells. We believe that it will provide a breakthrough in cancer immunotherapy. We pioneered HPV prophylactic vaccines with new innovations and we would like to expand this tradition to therapeutic setting, said DKFZs Dr. Prof. Gissmann, who will initiate the preclinical research program.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

Read the original here:
QualityStocks News - Power of the Dream Ventures Subsidiary Partners with German Cancer Research Center to Tackle HPV ...

This entry was posted in Uncategorized. Bookmark the permalink.

Comments are closed.